Bizarre Patents
Pneumatic Shoe Lacing Apparatus
This invention provides a pneumatic shoe lacing apparatus for the pneumatic lacing of shoe.
PatentStorm News
Make the Most of Our Site
See this month's Top Inventors and Most Cited Patents.
Stay on top of the latest innovations by subscribing to an RSS feed.
Registered users: Manage your profile.
| Application No. | Application Title | Issue Date |
| 20120107298 | Use of LCAT for Treating Anemia and Red Blood Cell Dysfunction Disclosed are methods for treating conditions characterized by anemia or red blood cells dysfunction by administering an agent that increases the level of endogenous LCAT or LCAT activity. Additionally disclosed are methods of treating conditions wherein red blood cells... | 05/03/2012 |
| 20120107297 | Method for therapeutic angiogenesis The present invention relates to the E2EPF UCP-VHL interaction and the uses thereof, more precisely a method for increasing or reducing VHL activity or level by regulating UCP activity or level to inhibit cancer cell proliferation or metastasis or to increase... | 05/03/2012 |
| 20120082677 | COMPOSITIONS FOR THE TREATMENT OF HCV AND HBV Therapeutic compositions for the treatment of viral hepatitis B (HBV) and hepatitis C (HCV) comprise antistreptokinase and antistreptolysine antibodies and/or tranexamic acid. Three antibodies against: polymerase, plasmin activators and fibrin are found in the blood of ... | 04/05/2012 |
| 20120082655 | Downregulation of SPY1 by p53 as an essential component of p53-mediated effects The present invention relates to a novel method of treating or preventing cancer as well as a novel method for diagnosing or monitoring cancer, wherein the cancer is caused by delayed entry to cellular senescence. More particularly, the present invention relates to a no... | 04/05/2012 |
| 20120082654 | Method For Preventing And Controlling Organisms That Infest Aqueous Systems Method for preventing and controlling organisms that infest aqueous systems in which one or more organic or inorganic compounds capable of releasing gas are present, comprising the step of dispersing on and/or in the aqueous mass a preparation comprising enzymes adapted... | 04/05/2012 |
| 20120070424 | Mutations on OAS1 Genes Modified amino acid sequences of OAS1 proteins in non-human primates, and genes related thereto, are provided.... | 03/22/2012 |
| 20120070416 | Macrocyclic Proline Derived HCV Serine Protease Inhibitors The present invention discloses compounds of Formula I or pharmaceutically acceptable salts, esters, or prodrugs thereof: which inhibit serine protease activity, particularly the activity of hepatitis C virus... | 03/22/2012 |
| 20120052083 | MUTANT CyaA POLYPEPTIDES AND POLYPEPTIDE DERIVATIVES SUITABLE FOR THE DELIVERY OF IMMUNOGENIC MOLECULES INTO A CELL The invention relates to mutant CyaA/E570Q+K860 polypeptides suitable for use as proteinaceous vectors for delivering one or more molecules of interest into a cell, in particular into a cell expressing the COM receptor. The invention further relates to polypeptide deriv... | 03/01/2012 |
| 20120045390 | Composition and Methods for the Diagnosis and Treatment of Tumor The present invention is directed to compositions of matter useful for the diagnosis and treatment of tumor in mammals and to methods of using those compositions of matter for the same.... | 02/23/2012 |
| 20120039881 | COMPOSITIONS AND METHODS FOR TREATING NEUROLOGICAL DISORDERS Methods and compositions for modulating GABA release in a subject are provided. A preferred embodiment provides a composition containing an effective amount of an ErbB4 ligand to enhance or promote GABA release, i.e., GABAergic transmission. The ErbB4 ligand can be an a... | 02/16/2012 |
| 20120039800 | Platinum Acridine Anti-Cancer Compounds And Methods Thereof Acridine containing cisplatin compounds are disclosed that show greater efficacy against cancer than other cisplatin compounds.... | 02/16/2012 |
| 20120039985 | DENDRITIC CELL MODULATION IN POST-ISCHEMIC WOUNDS Compositions and methods useful for targeted depletion or modulation of dendritic cells are provided. The compositions and methods can be used to promote healing of ischemia-related injury, including ischemia-reperfusion injury. Disclosed are a variety of dendritic cell... | 02/16/2012 |
| 20120027745 | ALANINE-GLYOXYLATE AMINOTRANSFERASE THERAPEUTICS The present invention relates to an alanine glyoxylate aminotransferase (AGXT) I340M therapeutic for use as a medicament or in a method of treatment, for example in the treatment of an AGXT-responsive condition. The AGXT I340M therapeutic is an AGXT I340M protein compri... | 02/02/2012 |
| 20120027742 | METHODS FOR TREATING ADULT RESPIRATORY DISTRESS SYNDROME We have discovered that the activated phosphorylated form of focal adhesion kinase (hereafter “FAKp”) strengthens the microvascular endothelial cell (EC) junctions that form a barrier in pulmonary endothelia, and the increased barrier helps to prevent acute lung inj... | 02/02/2012 |
| 20120027744 | MODIFIED HEPARINASE III AND METHODS OF SEQUENCING THEREWITH The invention relates to heparinase III and mutants thereof. Modified forms of heparinase III having reduced enzymatic activity which are useful for a variety of purposes, including sequencing of heparin-like glycosaminoglycans (HLGAGs), removing active heparan sulfate ... | 02/02/2012 |
| 20120021045 | Methods for Inhibiting Cancer Cell Proliferation The present invention concerns methods of treating cancer and methods of inhibiting cancer cell proliferation, particularly methods of treating breast cancer.... | 01/26/2012 |
| 20120014937 | Human Beta-Adrenergic receptor kinase polypeptide and methods Various embodiments of the invention provide human kinases and phosphatases (KPP) polypeptides and polynucleotides which identify and encode KPP. Embodiments of the invention also provide expression vectors, host cells, antibodies, agonists, and antagonists. Other embod... | 01/19/2012 |
| 20120014938 | Angiogenic Tyrosyl t-RNA Synthetase Compositions and Methods The present invention provides an isolated tyrosyl tRNA synthetase (TyrRS) polypeptide variant which comprises (a) a Rossmann fold region or a portion thereof, preferably including an α5 coil; and (b) an anticodon recognition domain or portion thereof, preferably inclu... | 01/19/2012 |
| 20120009172 | INTRAVENOUS AND ORAL DOSING OF A DIRECT-ACTING AND REVERSIBLE P2Y12 INHIBITOR The invention provides methods and compositions for rapid and reversible inhibition of platelet aggregation in human subjects in need thereof by administering compounds of the formula: alone or in combination... | 01/12/2012 |
| 20120003203 | Compositions and Methods for Treating S. Pneumoniae Infection The present invention relates to novel compounds that are useful for inhibition and prevention of pathogen cell adhesion and cell adhesion-mediated pathologies. This invention also relates to pharmaceutical formulations comprising these compounds and methods of using th... | 01/05/2012 |
| 20110318326 | Compositions and Methods The invention relates to a method for alleviating the inhibition of neurite outgrowth from a neurone, wherein said neurone comprises a Nogo receptor, said method comprising contacting said neurone with a composition capable of causing phosphorylation of a Nogo receptor,... | 12/29/2011 |
| 20110318325 | Inositol Pyrophosphates Determine Exocytotic Capacity The invention provides reagents and methods for treating type II diabetes, as well as methods for identifying compounds for treating type II diabetes.... | 12/29/2011 |
| 20110318351 | NOVEL METHODS OF CANCER DIAGNOSIS AND THERAPY TARGETED AGAINST A CANCER STEM LINE Improved methods for treatment of cancer which involve the targeting of slow-growing, relatively mutationally-spared cancer stem line are provided. These methods are an improvement over previous cancer therapeutic methods because they provide for very early cancer treat... | 12/29/2011 |
| 20110311443 | PHARMACEUTICAL COMPOSITION AND METHOD FOR IDENTIFYING A CANCEROUS AND/OR AN INFLAMMATORY DISEASE IN A PATIENT The invention relates to a method for treating a cancerous and/or an inflammatory disease in a patient, comprising internally administering to the patient an effective amount of a pharmaceutical preparation blocking the biological activity of at least one protein cluste... | 12/22/2011 |
| 20110311506 | PIGGYBAC TRANSPOSON VARIANTS AND METHODS OF USE The present invention provides hyperactive piggyBac transposons, in particular hyperactive piggyBac transposons from Trichoplusia ni (cabbage looper moth) that transpose at a higher frequency than wildtype. The invention also features integration defective piggyB... | 12/22/2011 |
| 20110311521 | Novel therapy for anxiety The present invention relates to a method of modulating, treating or effecting prophylaxis of a subject having anxiety or at risk of developing symptoms of anxiety, said method being characterized in that a therapeutically effective amount of a modulator of chondroitin ... | 12/22/2011 |
| 20110305682 | Compositions and Methods for Treating S. Pneumonia Infection The present invention relates to novel compounds that are useful for inhibition and prevention of pathogen cell adhesion and cell adhesion-mediated pathologies. This invention also relates to pharmaceutical formulations comprising these compounds and methods of using th... | 12/15/2011 |
| 20110305737 | Multi-Active Microtargeted Anti-Aging Skin Cream Polymer Technology A comprehensive, single agent cosmetic cream or lotion containing a high number of ingredients that target anti-aging in a defined manner. The cream or lotion contains a high number and variety of active substances that demonstrate excellent safety and efficacy in all o... | 12/15/2011 |
| 20110300115 | USE OF INDUCTOR AGENTS GSE24.2 FOR PRODUCING PHARMACEUTICAL COMPOSITIONS FOR TREATING ILLNESSES RELATING TO CELLULAR SENESCENCE This invention describes the use of an inductor or activator compound GSE24.2 for producing a medicament or pharmaceutical composition for treating a preferably human illness or pathological situation caused by a senescence process. Said pharmaceutical composition can b... | 12/08/2011 |
| 20110302675 | CONTROL OF VIRAL AND BACTERIAL INFECTION BY ANTIMICROBIAL PEPTIDES RETROCYLIN AND/OR PROTEGRIN EXPRESSED IN CHLOROPLASTS Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to ex... | 12/08/2011 |
| 20110300109 | COMPOSITIONS AND METHODS FOR TREATING CANCER The present invention is based, in part, on our discovery of compositions and methods that can be used to systemically deplete arginine and thereby treat arginine-dependent cancers. Our studies indicate that administering a composition that depletes arginine directly to... | 12/08/2011 |
| 20110293593 | SIVA 2 STABILIZATION The present invention relates to modulation of SIVA2 stability by N-acetylglucosamine, phosphorylation of ubiquitination in treatment or prevention of diseases, disorders or conditions.... | 12/01/2011 |
| 20110289605 | Animal Model for Osteoarthritis and Intervertebral Disc Disease Provided herein is a transgenic animal whose genome comprises a first nucleic acid sequence encoding a fusion polypeptide, wherein the fusion polypeptide comprises a Cre recombinase and a mutated ligand binding domain of human estrogen receptor (CreER), wherein the firs... | 11/24/2011 |
| 20110286984 | GENE ENCODING HUMAN GLUCOKINASE MUTANT, ENZYME ENCODED BY THE SAME, RECOMBINANT VECTORS AND HOSTS, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF, METHODS FOR TREATING AND PREVENTING DISEASES Gene encoding human glucokinase mutant is provided. The gene has the nucleotide sequence chosen from the nucleotide sequence listed as SEQ ID NO:2 and the nucleotide sequence wherein the ORF region encodes the same amino acid sequence as the one encoded by ORF region (p... | 11/24/2011 |
| 20110274681 | HUMAN E3ALPHA UBIQUITIN LIGASE FAMILY The present invention relates to a novel polypeptide encoding a protein which is the full length human ortholog of E3α ubiquitin ligase. The invention also relates to vector, host cells, antibodies and recombinant methods for producing the polypeptide. In addition, the... | 11/10/2011 |
| 20110269703 | METHOD FOR TREATING OR PREVENTING THROMBOSIS USING DABIGATRAN ETEXILATE OR A SALT THEREOF WITH IMPROVED SAFETY PROFILE OVER CONVENTIONAL WARFARIN THERAPY A method for preventing stroke in a patient suffering from atrial fibrillation, wherein the patient has at least one risk factor for major bleeding events, the method comprising administering to the patient 110 mg b.i.d. of dabigatran etexilate, optionally in the form o... | 11/03/2011 |
| 20110262453 | Markers for Assessing the Susceptibility of Cancer to IGF-1R Treatment The present invention relates to a method of predicting response of a cancer cell tissue to IGF-IR treatment. The inventors have observed a direct relationship between the expression of survivin, ErbB3 and E-cadherin and the response of cancer cells to IGF-IR tre... | 10/27/2011 |
| 20110256119 | NOVEL USES OF GRS PROTEINS OR FRAGMENTS THEREOF The present invention is related to a anticancer composition comprising full length GRS protein or a fragment thereof, a nucleic acid encoding the GRS protein or a fragment thereof. Since the GRS proteins or fragments thereof have activity to induce apoptosis of cancer ... | 10/20/2011 |
| 20110250179 | METHODS FOR TREATMENT AND DIAGNOSIS OF CANCER The present invention relates to methods for the treatment of cancer based on the induction of the choline kinase beta (hereinafter ChoKβ) activity as well as to methods for the design of personalized therapies and for determining the response of an agent capable of in... | 10/13/2011 |
| 20110243914 | SHIGA TOXIN B-SUBUNIT AS A VECTOR FOR TUMOR DIAGNOSIS AND DRUG DELIVERY TO GB3 EXPRESSING TUMORS The invention relates to new compounds for cancer therapy or diagnosis and more specifically to the use of a non-toxic B subunit of Shiga toxin mutant as a vector for diagnostic products or drugs in over-expressing Gb3 receptor cells, such compounds having th... | 10/06/2011 |
